

TB Saracen Global Income and Growth Fund

April 2019

SARACEN
share success




Fund Overview

- Objective: to provide a degree of income to investors with the aim of building capital through investing in a portfolio of primarily global equities.
- Focus: on identifying leading global businesses with lower risk and share valuations that underestimate their prospects.
- Research: we conduct intensive proprietary research focusing on businesses' long-term earnings potential.
- Risk: we model a 'worst-case' scenario into our share valuation methodology and abide by strict sector limits.
- Process: Disciplined, structured and repeatable.
- Conviction Portfolio: high active share and highly differentiated.
- Both fund managers have significant personal investments in the fund.

Performance Chart*

Performance since launch (%)

— TB Saracen Global Income & Growth Fund B Acc
— IA Global Equity Income Sector (TR)



*Source: Financial Express, as at 30th April 2019.

Total Return, Bid to Bid, GBP terms. Past performance is not a reliable indicator of future results. The value of your investment and the income derived from it can go down as well as up and you may not get back the money you invested.

Cumulative Performance after all ongoing charges to 30 April 2019

	1 month	3 months	1 year	3 years	5 years	Since launch*
TB SGIG B Acc	+4.4%	+8.7%	+2.5%	+43.9%	+49.5%	+112.4%
Sector Average	+3.1%	+7.3%	+7.8%	+38.5%	+52.5%	+97.5%
Quartile Ranking	1	2	4	2	3	2

Source: Financial Express; *launch date 07 June 2011

Sector: IA Sector (Global Equity Income)

FOR PROFESSIONAL INVESTORS ONLY

Retail investors should consult their financial advisers

FUND DETAILS

(as at 30th April 2019)

Fund size: £123m
Launch date: 07/06/11
Historic yield: 3.3%

No. of holdings: 41
Active share: 93%
Beta: 0.94

Source: Bloomberg as at 30/04/19

Turnover: <20%
Denomination: GBP
Valuation point: 12:00 noon

XD date: 2 Jan
1 July

Pay date: 28/29 Feb
31 Aug

Fund prices:
B Accumulation: 211.95p
B Distribution: 168.86p

Policy is not to charge a dilution levy except in exceptional circumstances.

ACD:
T. Bailey Fund Services Limited

Graham Campbell
Chief Executive Officer

David Keir
Executive Director



Graham Campbell joined Saracen in 2011 from Edinburgh Partners, where he was one of the founding partners and director. He has managed the Fund since launch. Graham has over 30 years of industry experience.

David Keir joined Saracen in 2013 and has managed the Fund since 2014. He has over 18 years of industry experience.




TB Saracen Global Income and Growth Fund

April 2019

SARACEN
share success



Fund Breakdown by Geography



Data as of 30th April 2019, Source: Bloomberg/Saracen Fund Managers

Monthly Commentary

Performance

This month, the total return for TB SGIG was +4.4%, compared to +3.1% for the IA Global Equity Income sector. Despite the strong start to the year, the fund remains attractively valued versus both the market and the peer group trading on 12.2X 2019 PER and yields 4.3%. The fund has delivered a total return of 112% and is ranked second quartile since launch.

FX

Currency movements had a negligible impact on the fund's absolute performance. Sterling was down 0.6% and 0.7% against the EUR and USD respectively, but was up 1.6% against the CHF.

Positives

Almost two-thirds of our holdings published their Q1 reports in April. In general, the results have been re-assuring and provided further evidence that the market had become far too bearish on the outlook for global growth. Saint Gobain (+14%) reported +5.7% LFL growth in Q1 and remain upbeat about their prospects for the rest of the year. Interpublic (+13%) delivered +6.4% organic growth in the quarter. Schneider (+6%) had a strong start to the year achieving +5.9% organic revenue growth and re-iterated full year targets. Michelin (+11%) continued to perform strongly after reporting 11% growth in profits in the quarter despite the difficult market backdrop. Valeo (+27%) had a strong month after achieving 400bps outperformance against the industry and re-iterating guidance. Banks, at last, had a better month! DBS (+12%) announced 9% growth in profits in the quarter. UBS (+12%) results were better than feared and both AIB (+8%) and HSBC (+7%) also performed well.

Negatives

The Pharmaceutical sector had a soft month after headlines about lower drug prices and "Medicare for all" plans. Our holdings in Merck (-6%), Pfizer (-6%) and Roche (-2%) were all impacted. Imperial Brands (-8%) shares fell after Altria reported disappointing volume numbers.

Portfolio Activity

We topped up our holdings in Asahi, Interpublic and ProSieben during the month. We sold Anta Sports on valuation grounds and took further profits in Cisco, Intel, Mondelez and Rio Tinto.

	ISIN	SEDOL	Bloomberg	EMX	Initial Charge	Annual Charge	Ongoing **
B Acc Shares	GB00B5B35X02	B5B35X0	SARBACC LN	SARGGIFA	0%	0.75%	0.99%
B Dis Shares	GB00B3XPLG55	B3XPLG5	SARGIGA LN	SARGGIFD	0%	0.75%	0.99%

** Source: T Bailey Fund Services Ltd

April – Attribution *

Top Contributors	Positive
Saint Gobain	+0.56%
Heidelberg Cement	+0.53%
DBS Group	+0.42%
Interpublic Group	+0.40%
Evonik	+0.39%
Top Detractors	Negative
Imperial Brands	-0.23%
Merck	-0.19%
Pfizer	-0.12%
Pandora	-0.12%
Roche	-0.10%

*Source: Bloomberg as at 30/04/19

Fund Breakdown

Top 10 Holdings	
Roche	4.2%
Saint Gobain	4.1%
Heidelberg Cement	4.0%
Evonik	3.7%
HSBC	3.7%
Johnson Matthey	3.7%
IBM	3.6%
Schneider	3.6%
DBS Group	3.4%
Svenska Handelsbanken	3.3%

Sector breakdown	
Financials	20.0%
Industrials	17.9%
Healthcare	15.3%
Basic Materials	12.5%
Technology	10.0%
Consumer Services	8.2%
Consumer Goods	8.1%
Oil & Gas	7.5%
Utilities	0.0%
Cash	0.5%

To place a deal or for further information contact:

T. Bailey Fund Services Limited (TBFS)
64 St. James's Street
Nottingham
NG1 6FJ

General Enquiries: 0115 988 8200
Dealing Line: 0115 988 8274
E-mail Dealing: clientservices@tbailey.co.uk

(Phone and email deals will only be accepted on completion of initial account set up and by prior agreement with TBFS)

T. Bailey Fund Services Limited is authorised and regulated by the Financial Conduct Authority (No. 190293).

Platform Partners



Important information:

This information should not be construed as an invitation, offer or recommendation to buy or sell investments, shares or securities or to form the basis of a contract to be relied on in any way and is by way of information only. Taxation levels, benefits and reliefs may all vary depending on individual circumstances and are subject to change. The historic yield reflects distribution payments declared by the fund over the previous year as a percentage of its share price. This document represents the views of Saracen Fund Managers Limited at the time of writing. Subscriptions will only be received and shares issued on the basis of the current Prospectus, Key Investor Information Document (KIID) and Supplementary Information Document (SID). These are available, in English, together with information on how to buy and sell shares, on-line at: www.tbaileyfs.co.uk.

Risk factors you should consider before investing:

The value of investments and the income from them may go down as well as up and you may get back less than the amount invested. **Past performance is not a guide to future performance.** A full list of the risks applicable to this Fund can be found in the Prospectus. All fund performance figures calculated on a single price basis. This Fund may not be appropriate for investors who plan to withdraw their money in the short-term (within 5 years). The Fund should be viewed as a medium to long-term investment only.

Investment Manager:

Saracen Fund Managers Ltd, 19 Rutland Square, Edinburgh, EH1 2BB. Tel: 0131 202 9100 and on-line at www.saracenfundmanagers.com. Saracen Fund Managers Limited is authorised and regulated by the Financial Conduct Authority. Registered in Scotland No. 180545.

Issued by Saracen Fund Managers Limited. Please note that Saracen Fund Managers Limited do not provide financial advice. If you have any doubt whether the TB Saracen Global Income and Growth Fund is suitable for you and you wish to receive advice you should contact your Financial Adviser.

Regulatory Status:

FCA Recognised: Yes
Scheme Type: OEIC (UCITS)

Issue date – 30th April 2019